Oramed Pharmaceuticals Retained Earnings (Accumulated Deficit) 2011-2024 | ORMP

Oramed Pharmaceuticals retained earnings (accumulated deficit) from 2011 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Oramed Pharmaceuticals Retained Earnings (Accumulated Deficit) 2011-2024 | ORMP

Oramed Pharmaceuticals retained earnings (accumulated deficit) from 2011 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$202.2B
Stryker (SYK)$143.3B
Boston Scientific (BSX)$130.1B
Medtronic (MDT)$112.5B
EssilorLuxottica (ESLOY)$111.7B
Lonza Group Ag (LZAGY)$45.4B
Haleon (HLN)$43.5B
GE HealthCare Technologies (GEHC)$39.3B
ResMed (RMD)$37B
Terumo (TRUMY)$29.6B
Koninklijke Philips (PHG)$25B
Zimmer Biomet Holdings (ZBH)$21.5B
Insulet (PODD)$18.8B
Baxter (BAX)$17.7B
Smith & Nephew SNATS (SNN)$10.6B
Bio-Rad Laboratories (BIO)$10.3B
BellRing Brands (BRBR)$9.1B
Demant (WILYY)$8.4B
Lantheus Holdings (LNTH)$6.1B
Haemonetics (HAE)$4.5B
TG Therapeutics (TGTX)$4.5B
ICU Medical (ICUI)$4.3B
Prestige Consumer Healthcare (PBH)$4B
Perrigo (PRGO)$3.6B
Neogen (NEOG)$3.5B
Envista Holdings (NVST)$3.5B
Agios Pharmaceuticals (AGIO)$3.4B
GN Store Nord (GNNDY)$3B
Shandong Weigao Medical Polymer (SHWGF)$3B
QuidelOrtho (QDEL)$2.9B